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SUMMARY 22 
Background: There is limited literature regarding adherence rates for the treatment of TB 23 
in children. We aimed to describe TB  treatment outcomes and adherence as well as to 24 
evaluate associated factors to poor adherence in  Mozambican children. 25 
Methods: This is a sub-study of a community TB incidence study among children <3years 26 
of age... Incomplete adherence included the sum of lost to follow-up cases plus those with 27 
a delay of >3 weeks to treatment completion. 28 
Results:  Fifty TB treatments were assessed. Forty-four (88.0%) patients completed 29 
treatment, 2(4.0%)  died during treatment and 4(8.0%) were lost to follow up.Incomplete 30 
adherence was observed in 31.3%(15/48) of cases and was associated with malnutrition or 31 
history of a migrant mother.   32 
Conclusion: Although treatment outcome is overall good, there is still a significant 33 
proportion of incomplete adherence. Further larger paediatric TB cohorts and qualitative 34 
approaches are needed to assess and confirm potential factors for non-adherence   35 
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TEXT 36 
BACKGROUND:  37 
According to studies performed in the smear positive adult population, tuberculosis (TB)  38 
therapy requires a high adherence rate of over 90% to facilitate cure(1,2). In adults, poor 39 
adherence has proven to increase the risk of morbidity, mortality and drug resistance at 40 
an individual and population level (3,4).  Incomplete adherence to long term therapy is 41 
one of the greatest challenges towards implementing the World Health Organization 42 
(WHO) End TB strategy, especially in Africa where the treatment success rate (81% in 43 
2013) has not reached the Stop TB 90% target (5,6).  44 
 45 
Children could account for 20-40% of all TB cases in high burden settings (7).  Young 46 
children are at highest risk of developing TB disease as well as rapid disease progression 47 
and mortality if diagnosis and treatment are delayed(8).  Adherence to TB treatment in 48 
children is complex and is  influenced by patient nd healthcare system factors, among 49 
others(9). It depends on the understanding and motivation of caretakers, who frequently 50 
have limited awareness of the disease (3,10). 51 
  52 
Studies on therapy for latent TB infection in children have shown low completion rates 53 
ranging from 44-78%(11). Treatment outcomes for pediatric TB disease in the African 54 
region have also shown high rates of poor outcomes (deaths, treatment failures and lost 55 
to follow-up) ranging from 10-19%(12–17).  However, there are few studies which report 56 
adherence and treatment duration(11). In addition,  there is very limited data on 57 
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associated barriers to anti-TB treatment in young children (11,18–20).  Therefore, the aim 58 
of this study was to describe the treatment outcomes and adherence to TB treatment and 59 
to evaluate factors associated with poor adherence in Mozambican children aged less 60 
than 3 years of age.  61 
 62 
 63 
METHODOLOGY  64 
 65 
Settings 66 
This study was conducted at the Manhiça District, Southern Mozambique, where the 67 
Manhiça Health Research Center runs a health and demographic surveillance system 68 
(HDSS) (21) . This setting has a high incidence of both TB and HIV with an estimated 69 
community-based incidence rate of TB among children < 3yr of 470/100,000 person-70 
years(22–24) and an estimated case detection rate of 41%(25). TB treatment is offered 71 
free at no cost to the patient at the health units and pediatric fixed-dose combinations are 72 
available following WHO 2010 dose recommendations(26). At the time of the study 73 
implementation, pediatric TB treatment for smear negative pulmonary cases and non-74 
severe forms of extrapulmonary TB, included an intensive phase of 2 months  of daily 75 
Isoniazid, Rifampicin and Pyrazinamide, followed by 4 months of daily Isoniazid and 76 
Rifampicin , with weekly and monthly clinical checks and drug collection respectively (27). 77 
All TB cases co-infected with HIV are managed in an integrated manner with the provision 78 
of cotrimoxazole preventive therapy and anti-retroviral therapy at TB clinics. 79 
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 80 
Study Design 81 
This is a sub-study of a larger prospective cohort study that assessed the minimum 82 
community incidence of TB among  young children (<3 years of age) over a 1-year period 83 
(October 2011- 2012), whose detailed methodology and findings have previously been 84 
published(22). Briefly, all presumptive TB cases were evaluated through physical and 85 
radiological examination, HIV and tuberculin skin testing, as well as smear microscopy and 86 
culture of both induced sputum and gastric aspirate samples. All participants had at least 87 
one follow up visit arranged within six months of recruitment. All TB cases were registered 88 
with the National Tuberculosis Program (NTP) and managed according to established 89 
national clinical guidelines. Treatment was always initiated at the Manhiça District 90 
Hospital (MDH) and patients ‘care was then transferred to their corresponding peripheral 91 
health unit, if applicable. For the purpose of this analysis, TB cases were defined as any 92 
case registered to initiate TB treatment at the NTP during the study period. In the 93 
incidence study, TB cases followed the  National Institute of Health (NIH) case definition 94 
for childhood TB (28) (See Box1). 95 
 96 
Data Collection and analysis 97 
Demographic and clinical data were obtained at  the initial visit, and follow-up clinical data 98 
were recorded at every subsequent visit. Other socio-demographic data was obtained 99 
through the HDSS 2012 data.   Information on the WHO treatment category, follow up 100 
visits, treatment outcome and adherence were retrospectively extracted from registers of 101 
6 
 
 
 
the NTP into a structured data collection tool. Delays in treatment completion were 102 
calculated based on the registered date of treatment initiation and treatment completion.  103 
 104 
Proportions were compared using the Fisher´s exact chi-squared  test. Prevalence ratio 105 
(PR) and its 95% confidence intervals (CI) were calculated from poison regression with robust 106 
standard errors to measure the strength of the association between clinical and 107 
demographic factors and adherence categories. Programmatic data from the NTP at the 108 
MDH for other age groups during the same period was used for comparison. Statistical 109 
software for analysis was Stata 11.2 (StataCorp. 2013. Stata: Release 11, StataCorp LP, 110 
Statistical Software, College Station, TX). 111 
 112 
Ethical considerations 113 
This study was approved by the Mozambican National Bioethics Committee 114 
(Ref.15/CNBS/2010). Written informed consent was obtained from the parents/caregivers 115 
of all children. 116 
 117 
 118 
RESULTS 119 
 120 
Fifty children under the age of three years consented to participate and initiated TB 121 
treatment in the district of Manhiça (Table 1). All were treated for drug susceptible TB, 9 122 
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cases were microbiologically confirmed on the basis of culture, although none of them 123 
was smear positive on microscopy for acid-fast bacilli. Of all children starting treatment, 124 
26 (52.0%) were male and 24 (48.0%) were HIV-infected. Although patients were 125 
followed-up in ten different peripheral health care centers, over 64.0% of cases were 126 
managed by two single health centers, one of which was the MDH (30.0%). 127 
 128 
All 50 cases had documented treatment outcomes: 44(88.0%) children successfully 129 
completed treatment, 2 (4.0%) died prior to treatment completion and 4 (8.0%) were lost 130 
to follow up (LTFU) . There were no treatment failures nor transferred cases. Among 131 
treatment success cases, 11 (25.0%) had a delay in treatment completion, 8 of which were 132 
males, over half HIV infected and one microbiologically confirmed TB case. Among the 133 
LTFU, 3 were males, all lived more than 2 km distance from the MDH, none fulfilled the 134 
study TB case definition and all were HIV-infected. Overall incomplete adherence (delayed 135 
plus LTFU) was reported in 31.3% (15 among the 48 patients who did not die) (Table 2). 136 
Figure 1 shows the distribution of the number of days from treatment initiation to 137 
treatment completion. Eleven cases finished treatment before the expected date, 8 of 138 
them 1-2 days earlier. One patient had a 74-day delay in treatment completion.  139 
 140 
Compared to other age groups registered at the MDH NTP during the same time period, 141 
we found a higher treatment success rate in children under 3 (88% versus 68,1% and 142 
72,5% among patients aged 3-15 years and >15 years respectively). However, incomplete 143 
adherence was similar in all groups. Figure2 shows adherence results for these three age 144 
categories (final numbers exclude deaths) .  145 
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 146 
Being malnourished at enrollment and having a mother with a history of migration in the 147 
previous 2 years to TB diagnosis were shown to be potential risk factors for incomplete 148 
adherence (PR 2.9 ; 95%CI:1.4-6.1 and PR 2.9; 95%CI:1.4-6.0 respectively, p-value<0.05) 149 
(Table 2).  150 
 151 
 152 
DISCUSSION 153 
 154 
Data on adherence to TB treatment in children is scarce. To our knowledge, this is the first 155 
study describing the profile and treatment outcomes among pediatric TB cases in 156 
Mozambique and one of the few reporting adherence and treatment outcomes in a well 157 
characterized cohort of young children. Although the overall treatment success rate(88%) 158 
was close to the 90% Stop TB target (6) there were still a significant proportion of pediatric 159 
TB cases with incomplete adherence (31.3%). Being malnourished and having a migrant 160 
mother were potential risk factors for incomplete adherence.  161 
We have previously reported a treatment success rate of 67.3% among children <3 years 162 
in Manhiça during 2006-2010 (25). The significant improvement observed in the current 163 
study compared to the previous years can be due to several reasons. Firstly, to the 164 
substantial recent decrease in mortality as improved TB/HIV care and treatment services 165 
are available at the health facilities. The proportion of patients who die during TB 166 
treatment has decreased from 17% during 2006-2010 to 4% in this study(29). Secondly, 167 
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improved outcomes may be due to a slight decrease in the number of LTFU (from 9.6% in 168 
2006-2010 to 8%) that could be influenced by the fact of being included in the 169 
epidemiological incidence study. Although the study had active follow up visits which 170 
could have positively influenced  treatment adherence, the univariate analysis did not 171 
show an association.   172 
The treatment success rate reported in this study  is similar to the 87% estimated by WHO 173 
for all new cases in 2012 for Mozambique (5). It decreased, however, in other age groups 174 
during the same period, reaching 68,1% and 72,5% in patients aged 3-15 year and >15 175 
year, respectively. While other authors have also found higher success rates with younger 176 
ages (11),  Hailu et al. found that  being above 5 years of age was a predictor of treatment 177 
success (18).  178 
Comparing TB treatment adherence results among different studies is difficult due to the 179 
large variations in the definitions of adherence found in the literature, particularly for 180 
childhood TB (11,19,17,30–33). As stated by Chang et al, it seems reasonable to consider 181 
LTFU and incomplete adherence as part of the same problem, with different levels of 182 
severity (34). Thus, for the purpose of this study we used a definition of incomplete 183 
adherence that includes LTFU plus delayed completion. Despite the differences in the 184 
definitions, the results in this study are similar to other pediatric reports from high burden 185 
countries (17,32,33,35). Unpublished results from a recent meta-analysis show a 186 
treatment success rate of 81% with 3% mortality, with large variations among the studies 187 
included (12). 188 
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We have identified several factors associated with incomplete adherence, many of them 189 
were expected and have been previously cited by other authors as predictors of poor 190 
outcome(13,36,37). Evidence of chronic or acute malnutrition at diagnosis was associated 191 
with incomplete adherence. Several studies have also reported poor TB outcomes among 192 
malnourished children (36,37) but in this study malnutrition was associated both with 193 
LTFU and death as well as with a delay in treatment completion. This suggests that beyond 194 
the deleterious immunological impact of malnutrition on TB progression, other aspects 195 
such as tolerance to drugs or, more importantly, the social context, have an impact on 196 
adherence and outcome. The importance of the caregiver child relationship has been 197 
shown to impact overall child survival and thus, the history of migration of the mother 198 
seems to impact treatment adherence and outcomes(38). Malnutrition was significantly 199 
associated with a history of a migrant mother, hospitalization at the time of diagnosis, and 200 
TB case definition, and thus the specific impact of these other variables on adherence is 201 
difficult to interpret.   202 
HIV co-infection is also a well-known risk factor for incomplete adherence in adults (2,39–42), and 203 
children(19,36),partly due to the increased pill burden and secondary effects. Because of the high 204 
treatment compliance rate (90%) required to facilitate cure and reduce the risk of rapid disease 205 
progression in children, the poor adherence observed among HIV-TB co-infected cases is cause for 206 
concern as it could lead to increased mortality.  Given the inherent difficulties in diagnosing 207 
pediatric TB, caregivers may sometimes reflect their uncertainty in the diagnosis by not fulfilling 208 
the treatment recommendations. This may be the underlying cause of the poorer adherence 209 
observed among cases not fulfilling the study TB definition. Moreover, TB diagnostic algorithms do 210 
not perform well among HIV co-infected children(28). Given the HIV co-infection rate observed 211 
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among confirmed and non-confirmed TB cases (10% and 51%, respectively), this may have played 212 
a role in hesitance of diagnosis and adherence to treatment. The gender difference observed in 213 
the current study was not statistically significant and needs to be further evaluated with larger 214 
sample sizes. Some adult studies have also noted a higher rate of incomplete adherence among 215 
males although this association needs to be further evaluated and may not be necessarily 216 
extrapolated to the pediatric population (42–45).  217 
 218 
There are several limitations to this study. Firstly, the small sample size of the cohort limits 219 
the ability to reach statistical significance for several potential associations (no 220 
multivariable logistic regression analysis was possible). Secondly, the analysis of 221 
adherence was performed using data measured indirectly with a retrospective design. In 222 
addition, the fact that most children starting treatment were part of a research study 223 
could have had a potential positive influence on adherence, although the study was 224 
focusing on case detection. Moreover, we did not register other common factors reported 225 
to influence adherence such as major side effects, who the main caregiver for the child 226 
was or the exact phase of the treatment where the main delay occurred.  Furthermore, 227 
the results may be biased given that TB under-reporting is more common in severe forms 228 
of the disease which die before treatment initiation. Finally, we did not capture common 229 
system failures such as drug stock rupture or health personnel absenteeism, which might 230 
lead to non-patient originated poor adherence. 231 
 232 
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In conclusion, although pediatric treatment outcome is overall good, there is still a 233 
significant proportion of incomplete adherence cases.  This study setting may have 234 
represented an improved health system scenario, so the true program performance may 235 
show worse indicators. Reinforcing the importance of timely treatment completion should 236 
remain a high priority. Successful treatment of pediatric TB requires the commitment and 237 
involvement of the corresponding caregiver. Further larger pediatric TB cohorts and 238 
qualitative research are needed to assess and eventually address potential risk factors for 239 
non-adherence. 240 
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LEGENDS TO FIGURES 420 
Figure 1. Duration of treatment among patients with treatment completion 421 
Definitions: Days of delay in treatment completion were calculated based on a standard 422 
treatment duration of 180 days for retreatment cases, final day was adjusted)  423 
Number of days in X axis are not in scale .  424 
Figure 2. Treatment and adherence outcomes among different age groups (2011-2012)  425 
This figure shows treatment outcome (treatment success vs. LTFU [lost to follow-up]) 426 
among patients who did not die and adherence results (full vs. incomplete adherence) 427 
among all age groups initiating TB treatment at the National Tuberculosis Program of the 428 
Manhiça Health Center (n= 867 to ≥ 15 yr; n= 82 to < 15 – 3 yr; n=56  to < 3yr). Excluded 429 
from this analysis are: dead and transferred cases as well as TB cases with number of 430 
treatment days missing.   431 
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TABLES 432 
BOX1: Relevant study definitions 433 
TB case: Any child registered to initiate TB treatment at the NTP during the study period. 
Study TB case:   Includes microbiologically confirmed plus probable cases (adapted from 
the standardized NIH case definition for childhood TB (28), full details on the classification 
are described elsewhere(22)).  
Confirmed TB case: compatible symptoms plus a positive culture with Mycobacterium 
Tuberculosis. 
Probable TB case:  fulfilling the following 3 criteria:  
(1) compatible symptoms unresolved at last clinical follow up visit (prior to any TB 
treatment initiation)  
(2) compatible chest radiograph: ≥1 of the following radiographic abnormalities: airway 
compression, lymphadenopathy, opacification, nodular picture, effusion, cavities, 
spondylitis or Ghon focus (46) 
(3) at least one of the following: TB exposure, positive TST (induration >5 mm for HIV or 
malnourished children and >10 mm for the rest of participants) or positive response to TB 
treatment. 
HIV infection: positive antibody test in children>18 months (Determine, Abbott 
Laboratories and confirmed with Unigold, Trinity Biotech); or positive HIV PCR in those 
<18 months; or a strong clinical suspicion with positive antibody test in the absence of a 
PCR result. 
Treatment outcomes for drug susceptible TB patients (5,47): 
Treatment success: the sum of patients: 
1. Cured: A pulmonary TB patient with bacteriologically confirmed TB at the 
beginning of treatment who was smear- or culture-negative in the last month of 
treatment and on at least one previous occasion) AND 
2.  Treatment completed: A TB patient who completed treatment without evidence 
of failure BUT with no record to show that sputum smear or culture results in the 
last month of treatment and on at least one previous occasion were negative, 
either because tests were not done or because results are unavailable. 
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Treatment failed: A TB patient whose sputum smear or culture is positive at month 5 or 
later during treatment. 
Died: A TB patient who dies for any reason before starting or during the course of 
treatment. 
Lost to follow up: A TB patient whose treatment was interrupted for 2 consecutive 
months or more. 
Not evaluated: A TB patient for whom no treatment outcome is assigned. This includes 
cases “transferred out” to another treatment unit as well as cases for whom the 
treatment outcome is unknown to the reporting unit. 
Adherence categories were defined as: 
Incomplete adherence. The sum of the following two exclusive categories and calculated 
over those patients who did not die:  
1. Lost to follow-up (patients whose treatment was interrupted for 2 consecutive 
months or more) AND  
2. Delayed completion (patients with a delay of 3 or more weeksbeyond the 
expected date (calculated as 6 months after treatment initiation) ) 
Full adherence. All treatment success cases with no delay in treatment completion.  
 
* NIH: National Institute of Health; NTP: National TB Program; TB: Tuberculosis; TST: 434 
tuberculin skin test 435 
 436 
  437 
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Table 1.- Clinical and Socio-demographic characteristics of TB cases <3yr at the time of 438 
TB diagnosis 439 
Table 1A.  Clinical and sociodemographic characteristics of TB cases <3yr at the time of TB diagnosis (N=50)  
Clnical     n (%) 
Sex (male) male   26 (52) 
  female   24 (48) 
Age in months, (Median [IQR])     19.8 
[14.6-
26.1] 
Age at diagnosis (months)         
  < 12   10 (20) 
  12 - 24   23 (46) 
  > 24   17 (34) 
BCG Scar †  present   43 (87.8) 
  absent   6 (12.2) 
HIV-coinfected yes   24 (48) 
  no   26 (52) 
TST α positive   21 (43.8) 
  negative   27 (56.2) 
Hospitalizations in previous year to TB diagnosis yes   20 (40) 
  no   30 (60) 
Nº outpatient consultations in previous year to TB 
diagnosis <10   36 (72.0) 
  ≥10   14 (28) 
Study TB cases definition  Confirmed   9 (18) 
  Probable   25 (50) 
  Possible   13 (26) 
  MTB infection/TB unlikely 3 (6) 
TB Compatible CXR yes   18 (36) 
  no   32 (64) 
Symptoms         
Cough >2 weeks yes   14 (28) 
  no   36 (72) 
Fever>2 weeks yes   6 (12) 
  no   44 (88) 
Wheeze yes   3 (6) 
  no   47 (94) 
Chronic or Acute Malnutrition yes   11 (22) 
  no   39 (78) 
Adenopathy  yes   1 (2) 
  no   49 (98) 
Contact of Pulmonary TB case (documented  or reported) yes   14 (28) 
  no   36 (72) 
Hospitalized at time of enrolment β yes   9 (18) 
  no   41 (82) 
Number of follow-up visits to the cohort study during course of TB treatment       
  < 2   11 (22) 
  ≥ 2   39 (78) 
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Denominator is n=50 except for α (n=48) and  † (n=49)           
BCG= Bacille Calmette Guerin; HIV= human immunodeficiency virus; IQR= interquartilic range; CXR= Chest X ray; TST= 
Tuberculine Skin Test;  
Definitions: Positive TST was defined as an induration >5 mm for HIV or malnourished children and >10 mm for the rest of 
participants. HIV infection was defined as positive antibody test in children >18 months (Determine, Abbott Laboratories 
and confirmed with Unigold, Trinity Biotech); or positive HIV polymerase chain reaction in those <18 months; or a strong 
clinical suspicion with positive antibody test in the absence of a polymerase chain reaction result. CXR were classified as 
compatible if presented ≥1 of the following radiographic abnormalities: airway compression, lymphadenopathy, 
opacification, nodular picture, effusion, cavities, spondylitis or Ghon focus.  
 
 
 
Sociodemographic         n (%) 
Distance to Peripheral Health Care Centers in Km (Median [IQR]) 1,68 [1.18-2.50] 
Distance to Peripheral Health Care Centers       
  < 1     30 (60) 
  2-5     15 (30) 
  > 5     5 (10) 
Distance to Manhiça Health Center Km (Median [IQR]) 12,46 [3.9-17.4] 
Distance to Manhiça Health Center       
  < 5km     16 (32) 
  ≥ 5 km     34 (68) 
Nº of people living in the house (median [IQR]) 6 [4-9] 
Nº of people living in the house       
  < 6     21 (42) 
  ≥ 6     29 (58) 
Number of children <15y living in the house‡     
  1 a 3     35 (80) 
  ≥ 4     9 (20) 
Children's birth order ‡         
  1th o 2nd     30 (68.2) 
  ≥ 3rd     14 (31.8) 
Children <15 yr at home ‡         
  1 a 4     26 (59.1) 
  ≥ 5     18 (40.9) 
Orphan (death of mother)     1 (2.0) 
Orphan (death of father)     4 (8) 
Death in the household in the previous 
year   14 (28) 
Migration of the mother  in previous 2 yr   8 (16) 
Migration of the father in previous 2 yr   16 (32.0) 
Migration in the household member    20 (40) 
SES†           
  Poorest     15 (30) 
  Less Poor     20 (40) 
Denominator is n=50 except for ‡ (n=44) and  † (n=35)    440 
IQR= interquartilic range ; SES:  Socio Economic Status  441 
Definitions: A household asset-based wealth index was used to categorize the household socio-economic 442 
status (SES) into 5 wealth quintiles. The 2 lowest quintiles were grouped as "poorest" and the remaining 3 443 
quintiles were renamed  "less poor" 444 
445 
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Table 2. Univariate analysis of predictor factors for incomplete adherence. 446 
      
Full 
Adherence† 
Incomplete 
Adherence‡     
      n (%) n (%) PR (95%CI) p value 
Total     33 (68.8) 15 (31.3)     
                  
Sex *                 
  Female   19 (82.6) 4 (17.4) Reference   
  Male    14 (56) 11 (44) 2.5 (0.9-6.9) 0.065 
HIV-coinfected               
  No   20 (80.0) 5 (20.0) Reference   
  Yes   13 (56.6) 10 (43.5) 1.9 (0.8-4.4) 0.080 
Study TB case definition             
  Possible-Unlikely 7 (50.0) 7 (50.0) Reference   
  Confirmed-Probable 26 (76.5) 8 (23.5) 0.5 (0.1-1.1) 0.072 
Nº outpatient consultations in previous year 
*           
  0 - 9   21 (61.8) 13 (38.2) Reference   
  ≥ 10   12 (85.7) 2 (14.3) 0.4 (0.1-1.5) 0.171 
Hospitalized at time of enrolment *             
  No   30 (75.0) 10 (25.0) Reference   
  Yes   3 (37.5) 5 (62.5) 2.5 (1.2-5.4) 0.088 
Symptom at enrolment: malnutrition*             
  No   30 (76.9) 9 (23.1) Reference   
  Yes   3 (33.3) 6 (66.7) 2.9 (1.4-6.1) 0.018 
Migration of the mother  in previous 2 yr *           
  No   31 (75.6) 10 (24.4) Reference   
  Yes   2 (28.6) 5 (71.4) 2.9 (1.4-6.0) 0.024 
                  
Death in the household in the previous year 
*           
  No   22 (61.1) 14 (38.9) Reference   
  Yes   11 (91.7) 1 (8.3) 0.2 (0.1-1.5) 0.073 
Nº of people living in the house             
  < 6   11 (55.0) 9 (45.0) Reference   
  ≥ 6   22 (78.6) 6 (21.4) 0.5 (0.2-1.1) 0.082 
Distance to the nearest Health Care Center           
  < 2 km   23 (76.7) 7 (23.3) Reference   
  ≥ 2 km   10 (55.6) 8 (44.4) 1.9 (0.8-4.4) 0.127 
 CI= confidence intervals; PR= prevalence ratio; HIV= human immunodeficiency virus; TB= tuberculosis   
† =Full adherence:  treatment completed on time with full adherence 
‡ = Incomplete adjerence includes a) delayed treatment completion plus b) treatment non completion;  
p values obtained through chi-squared test or Fisher´s exact test (when applicable*)     
Only those variables with p-values < 0.2 are shown          
A significant association was found between the variable malnutrition and hospitalization (p=0.02, migration of the 
mother (p=0.001) and TB case definition (P=0.002)       
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